IP Library › Granted Patent US 12,692,515
Granted Patent B2
US 12,692,515 · App. 18/000,574 · Granted Jul 28, 2026

Artificial expression constructs for selectively modulating gene expression in inhibitory neocortical neurons

Inventors: Tanya Daigle (Lake Forest Park, WA); Lucas T. Graybuck (Seattle, WA); Edward Sebastian Lein (Mercer Island, WA); Boaz P. Levi (Seattle, WA); John K. Mich (Seattle, WA); Adriana Estela Sedeño Cortés (Seattle, WA); Bosiljka Tasic (Seattle, WA); Jonathan Ting (Lake Forest Park, WA); Miranda Walker (Ann Arbor, MI); Hongkui Zeng (Seattle, WA)
Assignee: Allen Institute
C12N15/86A61K9/0019A61K9/0085C12N15/11C12N2510/02C12N2750/14141
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,692,515
App. No.
18/000,574
Filed
Dec 2, 2022
Granted
Jul 28, 2026
Kind
B2
Art Unit
1638
USPC
435/320.1
Abstract

Artificial expression constructs for selectively modulating gene expression in selected central nervous system cell types are described. The artificial expression constructs can be used to selectively express synthetic genes or modify gene expression in inhibitory neocortical GABAergic neurons including somatostatin GABAergic neurons, parvalbumin GABAergic neurons, vasointestinal peptide GABAergic neurons, Lamp5 GABAergic neurons, and in some instances astrocytes.

Claims (21)

1 . An artificial expression construct comprising (i) an enhancer selected from SEQ ID NO: 11, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 162, SEQ ID NO: 164, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 166, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 163, and SEQ ID NO: 165 or a sequence having at least 95% sequence identity to the sequence as set forth in any of SEQ ID NOs: 1-25, 132-166; (ii) a promoter; and (iii) a heterologous encoding sequence.

2 . The artificial expression construct of claim 1 , wherein the heterologous encoding sequence encodes a fluorescent protein.

3 . The artificial expression construct of claim 1 , wherein the heterologous encoding sequence encodes a neurotransmitter.

4 . The artificial expression construct of claim 1 , wherein the artificial expression construct is associated with a capsid that crosses the blood brain barrier.

5 . The artificial expression construct of claim 4 , wherein the capsid comprises PHP.eB, AAV9, AAVrh.10, AAV-BR1, AAV-PHP.S, AAV-PHP.B, or AAV-PPS.

6 . The artificial expression construct of claim 1 , wherein the artificial expression construct includes or encodes a skipping element.

7 . The artificial expression construct of claim 6 , wherein the skipping element comprises a T2A peptide, P2A peptide, E2A peptide, F2A peptide, or an internal ribosome entry site (IRES).

8 . The artificial expression construct of claim 1 , wherein the artificial expression construct is within a viral vector.

9 . The artificial expression construct of claim 8 , wherein the viral vector comprises a recombinant adeno-associated viral (AAV) vector.

10 . A method for selectively expressing a heterologous encoding sequence within a population of cells in vivo or in vitro, the method comprising providing an administrable composition comprising an artificial expression construct, wherein the artificial expression construct comprises (i) and enhancer having a sequence as set forth in SEQ ID NO: 11, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 166, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 163, and SEQ ID NO: 165 or a sequence having at least 95% sequence identity to the sequence as set forth in any of SEQ ID NOs: 1-25, 132-166; (ii) a promoter; and (iii) a heterologous encoding sequence

in a sufficient dosage and for a sufficient time to a sample or subject comprising the population of cells thereby selectively expressing the heterologous encoding sequence within the population of cells.

11 . The method of claim 10 , wherein the heterologous encoding sequence encodes a fluorescent protein or a neurotransmitter.

12 . The method of claim 10 , wherein the providing comprises pipetting to a brain slice.

13 . The method of claim 12 , wherein the brain slice comprises an Sst GABAergic neuron, a Pvalb GABAergic neuron, a Pvalb/Sst GABAergic neuron, a Vip GABAergic neuron, a Lamp5 GABAergic neuron, and/or an astrocyte.

14 . The method of claim 12 , wherein the brain slice comprises a Lamp5_Lhx6 GABAergic neuron.

15 . The method of claim 10 , wherein the providing comprises administering to a living subject.

16 . The method of claim 15 , wherein the living subject is a human, non-human primate, or a mouse.

17 . The method of claim 15 , wherein the administering to a living subject is through injection.

18 . The method of claim 17 , wherein the injection comprises intravenous injection, intraparenchymal injection into brain tissue, intracerebroventricular (ICV) injection, intra-cisterna magna (ICM) injection, or intrathecal injection.

19 . An artificial enhancer comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 copies of a sequence as set forth in SEQ ID NO: 161, SEQ ID NO: 163, or SEQ ID NO: 165 or a sequence having at least 95% sequence identity to the sequence as set forth in SEQ ID NO: 161, SEQ ID NO: 163, or SEQ ID NO: 165.

20 . The artificial enhancer of claim 19 , comprising the sequence as set forth in SEQ ID NO: 162, SEQ ID NO: 164, or SEQ ID NO: 166 or a sequence having at least 95% sequence identity to the sequence as set forth in SEQ ID NO: 162, SEQ ID NO: 164, or SEQ ID NO: 166.

Assignments (4)
LICENSE Recorded Nov 4, 2024
From: ALLEN INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 069299/0215 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED AT REEL: 062043 FRAME: 0083. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Dec 21, 2022
From: DAIGLE, TANYA; GRAYBUCK, LUCAS T.; LEIN, EDWARD SEBASTIAN; LEVI, BOAZ P.; MICH, JOHN K.; SEDENO CORTES, ADRIANA ESTELA; TASIC, BOSILJKA; TING, JONATHAN; WALKER, MIRANDA; ZENG, HONGKUI
To: ALLEN INSTITUTE
Reel/Frame 062201/0433 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2022
From: TING, JONATHAN; LEVI, BOAZ P.; TASIC, BOSILJKA; GRAYBUCK, LUCAS T.; DAIGLE, TANYA; MICH, JOHN K.; LEIN, EDWARD SEBASTIAN; ZENG, HONGKUI
To: ALLEN INSTITUTE
Reel/Frame 062043/0046 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2022
From: DAIGLE, TANYA; GRAYBUCK, LUCAS T.; LEIN, EDWARD SEBASTIAN; LEVI, BOAZ P.; MICH, JOHN K.; SEDENO CORTES, ADRIANA ESTELA; TASIC, BOSILJKA; TING, JONATHAN; WALKER, MIRANDA; ZENG, HONGKEI
To: ALLEN INSTITUTE
Reel/Frame 062043/0083 →
Continuity (2)
Provisional Application 63034794 · Jun 4, 2020
Related Publication 20230212608A1 · Jul 6, 2023
References Cited (49)
US 5753506A · Johe · 1998 [cited by applicant]
US 5766948A · Gage · 1998 [cited by applicant]
US 5851832A · Weiss · 1998 [cited by applicant]
US 5948428A · Lee · 1999 [cited by applicant]
US 6001654A · Anderson · 1999 [cited by applicant]
US 6395546B1 · Zobe · 2002 [cited by applicant]
US 6812339B1 · Venter · 2004 [cited by examiner]
US 10113201B2 · Davuluri · 2018 [cited by examiner]
US 11001841B2 · Lee · 2021 [cited by examiner]
US 20040087028A1 · Cunningham · 2004 [cited by applicant]
US 20120308530A1 · Hu · 2012 [cited by applicant]
US 20120329714A1 · Shingo · 2012 [cited by applicant]
US 20160208243A1 · Zhang · 2016 [cited by applicant]
US 20180030425A1 · Joung · 2018 [cited by applicant]
WO WO2001036623A2 · 2001 [cited by applicant]
WO WO2017184768A1 · 2017 [cited by applicant]
WO WO2019199867A1 · 2019 [cited by applicant]
WO WO2020076614A1 · 2020 [cited by applicant]
WO WO2020097121A1 · 2020 [cited by applicant]
Search Report and Written Opinion for European Application No. 21818145.1, Dated Jun. 24, 2024, 17 pages. [cited by applicant]
Graybuck, et al., “Prospective, brain-wide labeling of neuronal subclasses with enhancer-driven AAVs”, retreived on Feb. 2, 2022 at URL:https://www.biorxiv.org/content/10.1101/525014v2.full, bioRixiv, Jan. 31, 2019. [cited by applicant]
Mich, et al., “Functional enhancer elements drive subcalss-seletive expression from ouse to pimate neocortex”, Cell Rep, vol. 34, No. 13, 2021, 108754, 54 pages. [cited by applicant]
Search Report and Written Opinion for European Application No. 21818145.1, Dated Sep. 16, 2024, 15 pages. [cited by applicant]
Choi, et al., “Optimization of AAV expression cassettes to improve packaging capacity and transgene expression on heurons”, Molecular Brain, vol. 7, No. 17, 2014, 10 pages. [cited by applicant]
Search Report and Written Opinion for International Application No. PCT/US2021/036028, mailed Dec. 2, 2021, 14 pages. [cited by applicant]
Abhyankar, et al., “A novel CpG-free vertebrate insulator silences the testis-specific SP-10 gene in somatic tissues: role for TDP-43 in insulator function,” J. Biol. Chem., vol. 282, No. 50, 2007, pp. 36143-36154. [cited by applicant]
Albright, et al., “Mapping the Structural Determinants Required for AAVrh.10 Transport across the Blood-Brain Barrier,” Mol. Ther., vol. 26, No. 2, 2018, pp. 510-523. [cited by applicant]
Bell, et al., “The protein CTCF is required for the enhancer blocking activity of vertebrate insulators,” Cell, vol. 98, No. 3, 1999, pp. 387-396. [cited by applicant]
Bibel, et al., “Generation of a defined and uniform population of CNS progenitors and neurons from mouse embryonic stem cells,” Nat. Protoc., vol. 2, No. 5, 2007, pp. 1034-1043. [cited by applicant]
Caldwell, et al., “Growth factors regulate the survival and fate of cells derived from human neurospheres,” Nat. Biotechnol., vol. 19, No. 5, 2001, pp. 475-479. [cited by applicant]
Chan, et al., “Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems,” Nat. Neurosci., vol. 20, No. 8, 2017, pp. 1172-1179. [cited by applicant]
Chatzi, et al., “Derivation of homogeneous GABAergic neurons from mouse embryonic stem cells,” Exp. Neurol., vol. 217, No. 2, 2009, pp. 407-416. [cited by applicant]
Chen, et al., “Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy,” Nat. Med., vol. 15, No. 10, 2009, pp. 1215-1218. [cited by applicant]
Chung, et al., “A 5′ element of the chicken beta-globin domain serves as an insulator in human erythroid cells and protects against position effect in Drosophila,” Cell., vol. 74, No. 3, 1993, pp. 505-514. [cited by applicant]
Chung, et al., “Characterization of the chicken beta-globin insulator,” PNAS USA., vol. 94, No. 2, 1997, pp. 575-580. [cited by applicant]
Deverman, et al., “Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain,” Nat Biotechnol., vol. 34, No. 2, 2016, pp. 204-209. [cited by applicant]
Gombash, et al., “Intravenous AAV9 efficiently transduces myenteric neurons in neonate and juvenile mice,” Front. Mol. Neurosci., vol. 7, No. 81, 2014, 11 pages. [cited by applicant]
Hu, et al., “Differentiation of human oligodendrocytes from pluripotent stem cells,” Nat. Protoc., vol. 4, No. 11, 2009, pp. 1614-1622. [cited by applicant]
Jinek, et al., “A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity,” Science, vol. 337, No. 6096, 2012, pp. 816-821. [cited by applicant]
Jinek, et al., “RNA-programmed genome editing in human cells,” Elife, vol. 2, 2013, 9 pages. [cited by applicant]
Liu, et al., “Genomic discovery of potent chromatin insulators for human gene therapy,” Nat. Biotechnol., vol. 33, No. 2, 2015, pp. 198-203. [cited by applicant]
Marchio, et al., “Brain endothelial cell-targeted gene therapy of neurovascular disorders,” EMBO Mol. Med., vol. 8, No. 6, 2016, pp. 592-594. [cited by applicant]
Naso, et al., “Adeno-Associated Virus (AAV) as a Vector for Gene Therapy,” BioDrugs., vol. 31, No. 4, 2017, pp. 317-334. [cited by applicant]
GenBank Accession No. NCT03612869 “Open-label, Single-arm, Multi-center Study of Intracerebral Administration of Adeno-associated Viral (AAV) Serotype rh.10 Carrying Human N-sulfoglucosamine Sulfohydrolase (SGSH) cDNA f… [cited by applicant]
Segal, David J., “Bacteria herald a new era of gene editing,” Elife, vol. 2, 2013, 3 pages. [cited by applicant]
Selot, et al., “Optimized AAV rh.10 Vectors That Partially Evade Neutralizing Antibodies during Hepatic Gene Transfer,” Front Pharmacol., vol. 8, 2017, 10 pages. [cited by applicant]
Shetty and Turner, “In vitro survival and differentiation of neurons derived from epidermal growth factor-responsive postnatal hippocampal stem cells: inducing effects of brain-derived neurotrophic factor,” J. Neurobiol… [cited by applicant]
Yang, et al., “Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10,” Mol. Ther., vol. 22, No. 7, 2014, pp. 1299-1309. [cited by applicant]
Zetsche, et al., “Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system,” Cell., vol. 163, No. 3, 2015, pp. 759-771. [cited by applicant]